Overview

* Kodiak Q2 net loss of $54.3 mln missed analyst expectations

* Operating income for Q2 beat estimates, driven by clinical study activities

* Cash position at $104.2 mln, supporting operations into 2026

Result Drivers

* CLINICAL TRIALS - Increased R&D expenses driven by active Phase 3 studies for tarcocimab, KSI-501, and KSI-101

* CASH POSITION - Cash reserves of $104.2 mln expected to support operations into 2026

* MANUFACTURING - Completion of commercial-scale batches at URSUS facility for upcoming BLA submissions

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 EPS -$1.03

Q2 Net Miss -$54.31 -$53.70

Income mln mln (3

Analysts

)

Q2 Beat -$55.51 -$57.60

Operatin mln mln (4

g Income Analysts

)

Q2 Basic -$1.03

EPS

Q2 $55.51

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and 3 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Kodiak Sciences Inc ( KOD ) is $3.50, about 143.4% below its August 12 closing price of $8.52

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)